What You Should Know:
– Tandem Diabetes Care and Abbott have joined forces to bring the first automated insulin delivery (AID) system in the US compatible with Abbott’s latest FreeStyle Libre 2 Plus sensor.
– The integration brings the benefits of advanced closed-loop technology to millions of Americans living with diabetes, helping them achieve better blood sugar control and manage their condition with greater ease.
Seamless Integration for Precise Control:
The t:slim X2 insulin pump, equipped with Control-IQ technology, now wirelessly connects with the FreeStyle Libre 2 Plus sensor. This continuous glucose monitoring (CGM) system delivers minute-by-minute glucose data directly to the pump and its accompanying app. Control-IQ then utilizes this real-time information to predict glucose levels 30 minutes ahead and automatically adjust insulin delivery every five minutes, preventing both hyperglycemia and hypoglycemia.
Key benefits for users
– Reduced burden: The integration simplifies diabetes management by eliminating finger pricks and the need for separate CGM devices.
– Improved blood sugar control: Control-IQ’s proactive insulin adjustments help prevent high and low blood sugar levels, leading to better overall glucose management.
– Personalized experience: The system is highly customizable, allowing users to adjust settings to suit their individual needs and preferences.
Abbott’s Innovation
The FreeStyle Libre 2 Plus sensor boasts several features that make it ideal for AID compatibility:
– 15-day wear time: This extended wear period reduces the need for frequent sensor changes, offering convenience and cost savings.
– Proven accuracy: The sensor delivers highly accurate glucose readings, ensuring reliable data for Control-IQ’s algorithms.
– Discreet and comfortable: The sensor is small and lightweight, making it comfortable to wear for extended periods.
“Tandem’s leadership in AID innovation is underscored with this milestone of launching the first insulin pump to be compatible with Abbott’s CGM technology in the U.S.,” said John Sheridan, president and chief executive officer of Tandem Diabetes Care. “This represents another step forward in our commitment to provide customizable solutions to help reduce burden and create new possibilities for people living with diabetes.”
